CD34 and breast cancer: In accordance with previously published data showing reduced primary tumour growth and CD34 positive vasculature in 4T1 mammary tumours treated with anakinra [24], our study also showed that inhibition of MDA-MB-231-IV tumour growth in bone following administration of anakinra was associated with reduced levels of CD34 positive blood vessels.